| Date | Title | Description |
| 29.08.2024 | The Surge of Cardiac Surgery: A Market in Motion | The global cardiac surgery market is on the rise. It’s a lifeline in a world grappling with cardiovascular diseases (CVDs). These diseases are silent killers, claiming over 17 million lives each year. As technology advances, the market is p... |
| 28.08.2024 | Cardiac Surgery Market to Exceed $24B Due to Global Shift Towards Minimally Invasive Surgeries (TAVI/TAVR and TMVr) | iData Research | VANCOUVER, BC, Aug. 28, 2024 /PRNewswire/ - In a world, where cardiovascular diseases (CVDs) remain a leading cause of death, the global cardiac surgery market has emerged as a cornerstone of life-saving interventions, driven by innovations... |
| 29.09.2022 | Analysts high on AtriCure following Converge AFib procedure update | [Image from AtriCure]Analysts have a positive outlook on AtriCure (Nasdaq:ATRC) following an investor webinar discussing the company’s Convergent procedure.
Convergent uses the company’s EPi-Sense system. Its epicardial-sensing electrodes a... |
| 16.02.2022 | AtriCure publishes first environmental, social, governance report | AtriCure (NASDAQ:ATRC) this month released its first environmental, social and governance (ESG) report that highlights the company’s corporate responsibility and sustainability initiatives.
Companies produce corporate responsibility for cor... |
| 03.11.2021 | AtriCure Reports Third Quarter 2021 Financial Results - Form 8-K | AtriCure Reports Third Quarter 2021 Financial Results
MASON, Ohio, November 3, 2021 - AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announce... |
| 13.08.2019 | AtriCure to Acquire SentreHEART, for Up To $300M | AtriCure, Inc.(NASDAQ:ATRC), a Mason, OH-based developer of treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, is to acquire SentreHEART, Inc., a Redwood City, California-based developer of percutaneous le... |
| 15.09.2016 | ReFlow Therapeutics Closes Oversubscribed Seed Round | |
| 13.04.2016 | Morning Read: Sean Parker pumps $250M into new immunotherapy institute | Atrial fibrillation treatment specialist AtriCure got a greenlight from the FDA for its cryoFORM Cryoablation Probe. — AtriCure
Merck KGaA loses FDA approval for fertility drug after abandoning postmarketing studies. — FiercePharmaMarketing... |
| 31.01.2014 | AtriCure Completes Acquisition of Estech | WEST CHESTER, Ohio—(BUSINESS WIRE)—Jan. 2, 2014—AtriCure, Inc. (Nasdaq: ATRC), a leading Atrial Fibrillation medical device provider, today announced the completion of the previously announced acquisition of Endoscopic Technologies, Inc. d/... |
| 30.10.2013 | AtriCure gains on surging Q3 sales, raised outlook | AtriCure (NSDQ:ATRC) shares added more than 8% today after the medical device company reported 3r-quarter sales that beat Wall Street’s forecast and raised its outlook for the rest of the year.
AtriCure posted losses of $2.7 million, or 13¢... |
| 03.05.2012 | AtriCure soars on Street-beating Q1 results | AtriCure (NSDQ:ATRC) shares gained nearly 15% this morning after it reported lower-than-expected losses and record revenues of $17.5 million for the 1st quarter.
The West Chester, Ohio-based atrial fibrillation device maker reported losses ... |
| 13.04.2012 | AtriCure CEO Drachman got 64% raise to $1.9M last year | Drachman’s salary in 2010 was $412,000, with a total compensation of $1.1 million. Most of his pay increase in 2011 came in the form of increased stock awards.
It’s pretty safe to say the average American worker can only dream of a 64 perce... |
| 17.03.2012 | CTO Todd Park takes startup thinking to public sector (Weekend Rounds) | BCRX challenges Biota patent wars, claims its hepatitis C compound was first. The experimental hepatitis C treatment that BioCryst Pharmaceuticals (NASDAQ:BCRX) wants to take into clinical trials this year has run into an unexpected hitch: ... |
| 12.01.2012 | AtriCure again cited by an analyst as likely acquisition target | That’s a reference to the company’s AtriClip system, a device used to block a thumb-sized pouch on top of the left side of the heart to reduce blood clots.
The company scored a huge win last month when an AtriCure ablation system received U... |
| 05.12.2011 | AtriCure eyes new stroke market for AtriClip heart device | But don’t expect the company to obtain clearance for the stroke indication any time soon: Piton said the clinical process to get the label will likely take several years.
Currently, the AtriClip device is cleared in the U.S. only for use in... |
| 17.11.2011 | AtriCure closes enrollment in ‘hybrid’ atrial fibrillation study | AtriCure said a staged approach would lessen the learning curve related to the hybrid procedure for clinicians. Additionally, the staged approach would alleviate some scheduling and logistical challenges, AtriCure CEO David Drachman said.
A... |
| 07.09.2011 | AtriCure: Is now the time for a strategic acquirer to step up? | “We’re coming upon a time in which AtriCure’s strategic value will increase over the next 12 to 18 months,” said Matt Dolan, an analyst with Roth Capital Partners. “But you could make an argument that the company is an attractive acquisitio... |
| 02.08.2011 | AtriCure expects FDA clearance of new cryoablation system next quarter | For its second quarter, AtriCure reported a loss of 6 cents per share, 1 cent worse than Wall Street analysts had expected. Revenue grew 18 percent to $16.8 million, which slightly exceeded Wall Street’s expectations.
The sales growth was d... |
| 01.07.2011 | AtriCure announces a mixed shelf offering of up to $50 million | AtriCure Inc. (NSDQ:ATRC) filed a mixed shelf offering with the U.S. Securities and Exchange Commission to sell up to $50 million through a combination of debt securities, common stock, preferred stock, warrants, depositary shares and units... |
| 28.06.2011 | Heart news: AtriCure sees big potential in ‘hybrid’ atrial fibrillation procedure | Cardiac medical device maker AtriCure Inc.’s (NSDQ:ATRC) sees big opportunity in a new "hybrid" procedure that treats atrial fibrillation with a combination of ablation from inside and outside of the heart.
But the Cincinnati-area... |
| 24.06.2011 | AtriCure sees big potential in ‘hybrid’ atrial fibrillation procedure | “It’s a huge opportunity for the company, one of their biggest opportunities to create value,” said Matt Dolan, a senior research analyst with Roth Capital Partners.
Thom Gunderson, a senior research analyst with Piper Jaffray, reiterated t... |
| 05.05.2011 | AtriCure aims for FDA approval with “hybrid” atrial fibrillation trial | The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure Inc.’s (NSDQ:ATRC) U.S. business, the company’s CEO sai... |
| 04.05.2011 | AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business | Drachman spoke with analysts in a conference call discussing AtriCure’s first-quarter financial results. The company’s quarterly loss narrowed to $1.3 million from $2 million in the year-earlier quarter. Last quarter, AtriCure reported its ... |
| 17.02.2011 | AtriCure climbs into the black for the first time | Cardiac surgical device maker AtriCure Inc. (NSDQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb.
The company’s fourth-quarter earnings were scant, $11,500, but still far exceeded the ... |
| 16.02.2011 | AtriCure reports first-ever profitable quarter | The majority of the company’s revenue, $13.3 million, came from the U.S.
The AtriClip is a clip used during heart surgery to exclude the left atrial appendage. This exclusion helps protect atrial fibrillation patients from strokes. AtriClip... |
| 03.12.2010 | AtriCure commences trial on hybrid procedure for treating atrial fibrillation | Cardiac medical device maker AtriCure Inc. (NSDQ:ATRC) has enrolled the first human subject in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhyth... |
| 02.12.2010 | Atricure enrolls first patient in atrial fibrillation trial | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 09.08.2010 | AtriCure posts smallest-ever net loss | Riding high on an approval to sell a major new product in the U.S., AtriCure Inc. (NSDQ:ATRC) posted its smallest net loss ever during the second quarter — $764,506, or 5 cents per diluted share.
A consensus of securities analysts surveyed ... |
| 04.08.2010 | AtriCure rides a-fib momentum to smallest quarterly loss | The company’s president and chief executive expects sales and market share to continue strengthening in the second half of the year despite hospital cost-cutting and other economic uncertainties.
“In terms of our outlook, we believe that th... |
| 16.06.2010 | AtriCure stock rises 20 percent on approval news | By Mary Vanac
Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ:ATRC) rose more than 20 percent Tuesday, a day after the Food & Drug Administration approved the company’s AtriClip system for sale in the United States.
AtriCure sh... |
| 15.06.2010 | AtriCure: A superhero wearing an underdog’s uniform? | In May, during his company’s first-quarter conference call with analysts, Drachman estimated the U.S. market for the AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion System at “approximately 185,000 patients representing a market ... |
| 11.05.2010 | AtriCure wins FDA nod, posts positive Q1 results | By Mary Vanac
Cardiac ablation systems maker AtriCure Inc. (NSDQ:ATRC) won a conditional nod from the Food & Drug Administration to evaluate the safety and efficacy of a hybrid procedure to treat patients with persistent forms of atrial... |
| 10.05.2010 | AtriCure gets FDA nod to try hybrid atrial fibrillation procedure | Atricure will try a “dual epicardial/endocardial procedure” (DEEP) on 30 patients at up to five U.S. medical the company said. Enrollment is expected to begin in the second half of the year.
The hybrid procedure combines surgical and cathet... |
| 03.03.2010 | Night Read (Ohio): US Endoscopy releases colonoscopy product | Ohio State UniversityPresident E. Gordon Gee and Battelle President and CEO Jeffrey Wadsworth testify this morning in support of science, technology, engineering and mathematics education reform before the House Committee on Science and Tec... |
| 22.02.2010 | AtriCure’s Q4 sales rise, losses narrow | By Mary Vanac
WEST CHESTER, Ohio — Despite several challenges in 2009 — like a Dept. of Justice investigation and related whistleblower lawsuit — AtriCure Inc. (NSDQ:ATRC) advanced toward profitability, added regulator approvals for its car... |
| 18.02.2010 | Despite challenges, AtriCure advanced toward profitability, added regulator approvals in 2009 | Gross profit was $41.8 million and gross profit margin was 76.6 percent in 2009, about the same as a gross margin of 76.1 percent in 2008, the company said.
Revenue for the fourth quarter was $13.8 million, up 14 percent from $12.1 million ... |
| 02.02.2010 | AtriCure to pay $3.8 million to settle Justice Department claims | AtriCure on Tuesday declined to elaborate on the terms of its definitive agreement with the Justice Department, saying the terms are “substantially identical” to those disclosed in November. Then, the company said it had set aside $3.8 mill... |
| 04.11.2009 | AtriCure tentatively settles Department of Justice probe, looks to future with AtriClip | The agreement includes AtriCure’s assertions that the company and its employees have not done anything wrong or illegal. Although AtriCure leaders believe they have good defenses against the lawsuit, “litigation could potentially last years... |
| 06.10.2009 | AtriCure gets European OK for company-critical AtriClip System | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 27.03.2009 | AtriCure gets FDA clearance to sell system to treat bad heart rhythms with cold | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | AtriCure rides a-fib momentum to smallest quarterly loss | Riding high on an approval to sell a major new product in the United States, AtriCure Inc. (NASDAQ: ATRC) posted its smallest net loss ever during the second quarter — $764,506, or 5 cents a diluted share.
A consensus of securities analysts... |
| - | AtriCure eyes new stroke market for AtriClip heart device | Medical device maker AtriCure (NASDAQ:ATRC) is looking to obtain regulatory clearance to use its AtriClip heart device on stroke patients.
The Cincinnati-area company is planning next year to begin a clinical trial that will investigate the... |
| - | AtriCure gets FDA nod to try hybrid atrial fibrillation procedure | Updated 8:10 p.m., May 10, 2010.
Atricure Inc. (NASDAQ: ATRC), the maker of cardiac surgical ablation systems, has received a conditional nod from the Food and Drug Administration (FDA) to evaluate the safety and efficacy of a hybrid proced... |
| - | AtriCure sees big potential in ‘hybrid’ atrial fibrillation procedure | Cardiac medical device maker AtriCure (NASDAQ:ATRC) sees big opportunity in a new “hybrid” procedure that treats atrial fibrillation with a combination of ablation from inside and outside of the heart.
But the Cincinnati-area company will l... |
| - | AtriCure: Is now the time for a strategic acquirer to step up? | Medical device giants looking to boost their atrial fibrillation product portfolios would do well to take a long, hard look at cardiac device-maker AtriCure (NASDAQ:ATRC).
Things have been looking up recently for Cincinnati-area AtriCure, a... |
| - | Night Read (Ohio): US Endoscopy releases colonoscopy product | News and notes from the day in MedCity, Ohio:
US Endoscopy, the endoscopy device design and manufacturing company in Mentor, has released the Entrada colonic overtube, which offers more control during colonoscopy in patients with tortuous s... |
| - | AtriCure: A superhero wearing an underdog’s uniform? | Shares of West Chester, Ohio-based AtriCure Inc. (NASDAQ: ATRC) rose more than 20 percent Tuesday, a day after the Food and Drug Administration approved the company’s AtriClip system for sale in the United States.
AtriCure shares rose as hi... |
| - | AtriCure CEO Drachman got 64% raise to $1.9M last year | AtriCure (Nasdaq:ATRC) CEO David Drachman’s compensation package received a 64 percent boost to $1.9 million last year.
The Cincinnati-based cardiac devicemaker paid Drachman about $1.5 million in stock and options and $450,000 in salary in... |
| - | Despite challenges, AtriCure advanced toward profitability, added regulator approvals in 2009 | WEST CHESTER, Ohio — Despite several challenges in 2009– like a Department of Justice investigation and related whistle-blower lawsuit–AtriCure Inc. advanced toward profitability, added regulator approvals for its cardiac surgical ablation ... |
| - | Atricure enrolls first patient in atrial fibrillation trial | Cardiac medical device maker AtriCure Inc. (NASDAQ:ATRC) has enrolled the first patient in a clinical trial designed to test a hybrid procedure on patients with persistent atrial fibrillation, a condition marked by irregular heart rhythm.
T... |
| - | AtriCure tentatively settles Department of Justice probe, looks to future with AtriClip | WEST CHESTER, Ohio — AtriCure Inc. said today that it has tentatively settled a whistle-blower lawsuit with the Department of Justice so that it can concentrate on newly launched technologies, as well as on clinical trials to bring more n... |
| - | AtriCure to pay $3.8 million to settle Justice Department claims | Updated 6:53 p.m.
WEST CHESTER, Ohio — AtriCure Inc. has agreed to pay the federal government $3.76 million to settle claims that it promoted its surgical cardiac ablation devices for unapproved uses, the Justice Department said today in a ... |
| - | AtriCure gets FDA clearance to sell system to treat bad heart rhythms with cold | CINCINNATI, Ohio — AtriCure Inc. in suburban Cincinnati, Ohio, has received U.S. Food and Drug Administration approval to sell a disposable medical device that uses extreme cold to treat abnormal heart rhythms.
The Cryo1Â system can be us... |
| - | Morning Read: Sean Parker pumps $250M into new immunotherapy institute | TOP STORIES
Internet billionaire Sean Parker is investing $250 million to create an institute to speed up the development and testing of immunotherapies, a hot area of cancer research. — MIT Technology Review, Reuters
LIFE SCIENCES
Atrial f... |
| - | AtriCure: Atrial fibrillation trial to be ‘inflection point’ for business | The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure’s (NASDAQ:ATRC) U.S. business, its CEO said.
The pivota... |
| - | AtriCure expects FDA clearance of new cryoablation system next quarter | Cardiology medical device maker AtriCure (NASDAQ:ATRC) expects to receive U.S. regulatory clearance for a new cryoablation system by the end of next quarter.
The company’s cryoICE BOX system would use extreme cold to freeze cardiac tissue i... |
| - | AtriCure closes enrollment in ‘hybrid’ atrial fibrillation study | Cardiac device company AtriCure (NASDAQ:ATRC) has closed a feasibility clinical trial into a so-called “hybrid” procedure to treat atrial fibrillation, citing a change of plans in the study’s protocol.
Cincinnati-area AtriCure’s DEEP AF fea... |
| - | CTO Todd Park takes startup thinking to public sector (Weekend Rounds) | A review of life science current events reported by MedCity News this week.
New national CTO plans to expand lean thinking to all federal agencies. If Todd Park can find entrepreneurs in federal agencies and unleash a flood of health data, ... |
| - | AtriCure gets European OK for company-critical AtriClip System | WEST CHESTER, Ohio — AtriCure has received approval in Europe for its AtriClip, a device that protects against clotting during certain heart procedures.
Europe’s granting of the CE Mark for the AtriClip Gillinov-Cosgrove Left Atrial Appenda... |
| - | AtriCure again cited by an analyst as likely acquisition target | Cardiac device company AtriCure (NASDAQ:ATRC) has again been identified by an equities analyst as a likely acquisition target for a big medical device firm.
Barrington Research listed Cincinnati-area AtriCure as among its top 15 stock picks... |
| - | AtriCure reports first-ever profitable quarter | Cardiac surgical device maker AtriCure Inc. (NASDAQ:ATRC) has reported its first-ever profitable quarter as sales of its AtriClip device continue to climb.
The company’s fourth-quarter earnings were scant, $11,500, but still far exceeded th... |
